# Madison Scientific

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/madison-scientific

- Industry: Medical Devices & Equipment
- Headquarters: Chicago, US
- Website: www.madisonscientific.com
- Total disclosed funding: $11M
- Latest round: Seed (Sep 8, 2025)
- Investors on record: 10

## About

Madison Scientific Inc. is a Chicago-based company focused on developing innovative medical devices and therapies for patients suffering from hydrocephalus, enhancing quality of life through advanced solutions. Founded in 2020 by co-founder Tyler Wanke, Madison Scientific Inc. is engaged in creating advanced medical devices aimed specifically at managing hydrocephalus. The company was founded in Chicago, US. In September 2025, Madison Scientific Inc. raised USD 3 million in seed funding from new investors mHUB, Heinz Ventures, Endeavor Health, Isthmus Project, Princeton Alumni Angels, Stateline Angels, and Central Illinois Angels. Individual and other unspecified investors also participated in the round.
 Madison Scientific specializes in the development of innovative solutions aimed at improving the quality of life for hydrocephalus patients. The company’s core product offerings include advanced medical devices and therapies designed to manage this neurological condition effectively. These products enhance cerebrospinal fluid management and are primarily utilized by patients diagnosed with hydrocephalus, as well as healthcare providers and institutions involved in patient care. Madison Scientific markets its products in North America and Europe, where there is a significant demand for effective hydrocephalus management solutions. Madison Scientific generates revenue through structured transactions with healthcare providers and medical institutions. The business model includes direct sales of medical devices and therapies, along with potential partnerships with healthcare organizations. Pricing strategies are tailored to reflect the specialized nature and effectiveness of their products. The company’s flagship products are sold directly to hospitals and clinics, ensuring that medical practitioners have immediate access to the necessary tools for managing hydrocephalus effectively, thereby supporting the company's revenue streams. The company plans to utilize the September 2025 funding to further develop intelligent technology aimed at treating neurological disorders.

## Funding rounds

- Seed, Sep 8, 2025, $3M — Central Illinois Angels, Endeavor Health, Heinz Ventures, mHUB, Stateline Angels, Princeton Alumni Angels, Isthmus Project, MedTech Angels, Impact Foundation
- Seed, Jan 10, 2025, $7.7M — WARF Ventures

## Investors

- WARF Ventures (https://capitalatlas.ai/funds/warf-ventures) — Seed
- Central Illinois Angels — Seed
- Endeavor Health — Seed
- Heinz Ventures (https://capitalatlas.ai/funds/heinz-ventures) — Seed
- mHUB (https://capitalatlas.ai/funds/mhub) — Seed
- Stateline Angels — Seed
- Princeton Alumni Angels — Seed
- Isthmus Project — Seed
- MedTech Angels — Seed
- Impact Foundation — Seed